External control arms in oncology: current use and future directions-Reference-Cited by-同舟云学术

External control arms in oncology: current use and future directions

Published:2022-04 Issue:4 Volume:33 Page:376-383
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mishra-Kalyani P.S.,Amiri Kordestani L.,Rivera D.R.,Singh H.,Ibrahim A.,DeClaro R.A.,Shen Y.,Tang S.,Sridhara R.,Kluetz P.G.,Concato J.,Pazdur R.,Beaver J.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference25 articles.

1. Synthetic and external controls in clinical trials - a primer for researchers;Thorlund;Clin Epidemiol,2020

2. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials;Seeger;Pharmacoepidemiol Drug Saf,2020

3. Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms;Burcu;Pharmacoepidemiol Drug Saf,2020

4. A Food and Drug Administration analysis of survival outcomes comparing the adjuvant paclitaxel and trastuzumab trial with an external control from historical clinical trials;Amiri-Kordestani;Ann Oncol,2020

5. Estimation of historical control rate for a single arm de-escalation study - application to the POSITIVE trial;Sun;Breast,2020

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations;Drug Safety;2024-08-05

2. Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases;Clinical and Translational Science;2024-08

3. Examining external control arms in oncology: A scoping review of applications to date;Cancer Medicine;2024-07

4. Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023;ESMO Open;2024-07

5. Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space;Pharmaceutical Statistics;2024-06-25